SCHEMBL26107075

SCHEMBL26107075

Cn1c(C2=CCC3(CC2)CCN(C=CC=O)CC3)c(-c2ncco2)c2c(N)ncnc21

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ RET P07949 2/20 0.32
▸ KDR P35968 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26105475 0.87 LRRK2 (0.32) —
SCHEMBL26107393 0.85 LRRK2 (0.31) —
SCHEMBL26109353 0.84 RET (0.32) RETKDR
SCHEMBL26109831 0.84 CYP3A4 (0.33) —
SCHEMBL26107612 0.84 — —
SCHEMBL26588968 0.83 NUDT14 (0.37) KDR
SCHEMBL30582521 0.83 NUDT14 (0.37) KDR
SCHEMBL26108120 0.83 LRRK2 (0.32) —
SCHEMBL26107398 0.83 — —
SCHEMBL26108781 0.83 BTK (0.35) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO claimed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback